Entrada Therapeutics, Inc.
TRDA
$6.09
-$0.70-10.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 79.48M | 172.22M | 210.78M | 215.23M | 239.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.48M | 172.22M | 210.78M | 215.23M | 239.40M |
| Cost of Revenue | 134.61M | 128.77M | 125.31M | 120.19M | 111.13M |
| Gross Profit | -55.14M | 43.45M | 85.48M | 95.04M | 128.27M |
| SG&A Expenses | 41.03M | 39.34M | 38.47M | 37.26M | 34.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 175.64M | 168.11M | 163.77M | 157.45M | 145.94M |
| Operating Income | -96.16M | 4.11M | 47.01M | 57.78M | 93.45M |
| Income Before Tax | -76.91M | 23.81M | 66.49M | 76.42M | 110.38M |
| Income Tax Expenses | -3.55M | -972.00K | 859.00K | 21.47M | 5.93M |
| Earnings from Continuing Operations | -73.35 | 24.78 | 65.63 | 54.95 | 104.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.35M | 24.78M | 65.63M | 54.95M | 104.44M |
| EBIT | -96.16M | 4.11M | 47.01M | 57.78M | 93.45M |
| EBITDA | -92.26M | 7.89M | 50.78M | 61.30M | 96.87M |
| EPS Basic | -1.78 | 0.87 | 1.99 | 1.68 | 3.09 |
| Normalized Basic EPS | -1.17 | 0.54 | 1.27 | 1.46 | 2.04 |
| EPS Diluted | -1.79 | 0.80 | 1.90 | 1.59 | 2.96 |
| Normalized Diluted EPS | -1.17 | 0.50 | 1.22 | 1.40 | 1.97 |
| Average Basic Shares Outstanding | 163.88M | 156.73M | 149.15M | 141.68M | 134.33M |
| Average Diluted Shares Outstanding | 166.09M | 160.26M | 153.98M | 144.30M | 138.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |